Rxivist logo

A Transferable Deep Learning Approach to Fast Screen Potent Antiviral Drugs against SARS-CoV-2

By Shiwei Wang, Qi Sun, Youjun Xu, Jianfeng Pei, Luhua Lai

Posted 28 Aug 2020
bioRxiv DOI: 10.1101/2020.08.28.271569

The COVID-19 pandemic calls for rapid development of effective treatments. Although various drug repurpose approaches have been used to screen the FDA-approved drugs and drug candidates in clinical phases against SARS-CoV-2, the coronavirus that causes this disease, no magic bullets have been found until now. We used directed message passing neural network to first build a broad-spectrum anti-beta-coronavirus compound prediction model, which gave satisfactory predictions on newly reported active compounds against SARS-CoV-2. Then we applied transfer learning to fine-tune the model with the recently reported anti-SARS-CoV-2 compounds. The fine-tuned model was applied to screen a large compound library with 4.9 million drug-like molecules from ZINC15 database and recommended a list of potential anti-SARS-CoV-2 compounds for further experimental testing. As a proof-of-concept, we experimentally tested 7 high-scored compounds that also demonstrated good binding strength in docking study against the 3C-like protease of SARS-CoV-2 and found one novel compound that inhibited the enzyme with an IC50 of 37.0 μM. Our model is highly efficient and can be used to screen large compound databases with billions or more compounds to accelerate the drug discovery process for the treatment of COVID-19. ### Competing Interest Statement The authors have declared no competing interest.

Download data

  • Downloaded 298 times
  • Download rankings, all-time:
    • Site-wide: 91,554
    • In bioinformatics: 8,062
  • Year to date:
    • Site-wide: 52,976
  • Since beginning of last month:
    • Site-wide: 24,698

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide